No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
JAZZ240816P100000
- 2.25
- -0.60-21.05%
15min DelayClose Jul 22 09:38 ET
2.85High2.25Low
2.85Open2.85Pre Close13 Volume27 Open Interest100.00Strike Price3.53KTurnover64.27%IV10.89%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry2.25Extrinsic Value100Contract SizeAmericanOptions Type-0.2576Delta0.0174Gamma34.83Leverage Ratio-0.1150Theta-0.0198Rho-8.97Eff Leverage0.0933Vega
Intraday
- 5D
- Daily
News
Jazz Pharmaceuticals Reprices $2.7 Billion Outstanding Balance of Term Loan Facility
Jazz Pharmaceuticals (JAZZ) said Monday it repriced the roughly $2.7 billion outstanding balance of its term loan facility, which is expected to yield annual interest savings of about $23 million.
Express News | Jazz Pharmaceuticals Announces Successful Completion of Term Loan Repricing and Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes Due 2026
BofA Securities Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $172
BofA Securities analyst Jason Gerberry maintains $Jazz Pharmaceuticals(JAZZ.US)$ with a buy rating, and maintains the target price at $172.According to TipRanks data, the analyst has a success rate
Buy Rating Upheld for Jazz Pharmaceuticals Amidst Potential for Growth and Strategic Revaluation
Express News | Jazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31, 2024
Jazz Pharmaceuticals' (NASDAQ:JAZZ) Earnings Trajectory Could Turn Positive as the Stock Climbs 5.5% This Past Week
As an investor its worth striving to ensure your overall portfolio beats the market average. But in any portfolio, there are likely to be some stocks that fall short of that benchmark. We regret
Comments
🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics(IOVA.US$ Phase 2
$Supernus Pharmaceuticals(SUPN.US$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US$ Phase 2a
$MorphoSys(MOR.US$ Phase 2
$Nuvation Bio(NUVB.US$ Phase 2
$ALX Oncology(ALXO.US$ Phase 2
$BioXcel Therapeutics(BTAI.US$ Phase 2
$Purple Biotech(PPBT.US$ Phase 2
$Arcus Biosciences(RCUS.US$ Phase 2
$Medicenna Therapeutics(MDNAF.US$ Phase 2b
$Affimed NV(AFMD.US$ Phase 2
$Barinthus Biotherapeutics(BRNS.US$ Phase 2b...
$Iovance Biotherapeutics(IOVA.US$ Phase 2
$Supernus Pharmaceuticals(SUPN.US$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US$ Phase 2a
$MorphoSys(MOR.US$ Phase 2
$Nuvation Bio(NUVB.US$ Phase 2
$ALX Oncology(ALXO.US$ Phase 2
$BioXcel Therapeutics(BTAI.US$ Phase 2
$Purple Biotech(PPBT.US$ Phase 2
$Arcus Biosciences(RCUS.US$ Phase 2
$Medicenna Therapeutics(MDNAF.US$ Phase 2b
$Affimed NV(AFMD.US$ Phase 2
$Barinthus Biotherapeutics(BRNS.US$ Phase 2b...
13
3
$Esperion Therapeutics(ESPR.US$ Esperion (ESPR) stock price has dropped from a recent high of $3.40 a share to $2.31 on FALSE claims of dilution. The price drop offers an amazing buying opportunity.
Huge News On Mar 25.2024 U.S. FDA Approved Broad Labels for NEXLIZET and NEXLETOL, now regular doctors can prescribe and Insurance will...
Huge News On Mar 25.2024 U.S. FDA Approved Broad Labels for NEXLIZET and NEXLETOL, now regular doctors can prescribe and Insurance will...
3
Despite Jazz Pharmaceuticals' revenue growth and profitability, its share price drop may signal unresolved issues. The long-term share price weakness could be a bad sign, yet contrarian investors might see a potential turnaround opportunity.
1
The low ROE and high debt usage of Jazz Pharmaceuticals make it a less exciting investment at the moment. The company's performance could be impacted if it was unable to borrow as easily in changing credit markets.
Jazz Pharmaceuticals' low P/S ratio is due to slower revenue growth compared to industry trend, leading to discomfort amongst shareholders and stock devaluation. Persisting sluggish growth may decrease P/S ratio even further unless fortunes change.
Read more
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.
Rana Hasan1 : List too long